Loading...
Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance
Reactivated androgen receptor (AR) signaling drives castration-resistant prostate cancer (CRPC). Novel AR targeting drugs abiraterone and enzalutamide have improved survival of CRPC patients. However, resistance to these agents develops and patients ultimately succumb to CRPC. Potential mechanisms o...
Na minha lista:
| Udgivet i: | Clin Pharmacol Ther |
|---|---|
| Main Authors: | , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
2015
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4715745/ https://ncbi.nlm.nih.gov/pubmed/26331358 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpt.256 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|